(December 15, 2016, 11:30 AM EST) -- WASHINGTON, D.C. — Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) argue in a Dec. 7 reply brief that drug companies failed to show why the U.S. Supreme Court should not answer whether the filing of an abbreviated new drug application (ANDA) is sufficient to subject Mylan to specific personal jurisdiction in any state where they might market the drug (Mylan Pharmaceuticals Inc., et al. v. Acorda Therapeutics Inc., et al. & Mylan Pharmaceuticals Inc. v. AstraZeneca AB, No. 16-360, U.S. Sup.)....